Skip to content
Briefings are running a touch slower this week while we rebuild the foundations.See roadmap
Pandemics and Biosecurity
2JUN

Why the 14% death rate is too low

3 min read
09:17UTC

Bundibugyo's confirmed case-fatality ratio sits near 14%, between seasonal flu's 0.1% and classic Zaire Ebola's 50%. With 906 suspected cases untested, that figure measures only the patients who lived long enough to reach a laboratory.

ScienceAssessed
Key takeaway

Bundibugyo's recorded 14% death rate counts only tested survivors, so the true lethality is almost certainly higher.

WHO bulletin DON605 recorded 18 deaths among 134 laboratory-confirmed Bundibugyo cases on 29 May, a confirmed case-fatality ratio near 14% 1. The case-fatality ratio measures the share of confirmed patients WHO die. At 14%, Bundibugyo ebolavirus sits well below the roughly 50% seen in classic Zaire Ebola and far above seasonal influenza's 0.1%.

That 14% is almost certainly an undercount. The same bulletin recorded a suspected-to-confirmed ratio of 6.8 to one for the outbreak's caseload, the breakdown detailed in this briefing's headline figures. For every patient the laboratory confirms, nearly seven more are suspected but untested, and many are dying before a swab reaches them.

The recorded lethality is therefore the lethality among those WHO lived long enough to be tested. People WHO die quickly, before any sample is taken, never enter the case-fatality calculation at all. Ever since the global emergency was declared on 17 May , the response has chased a transmission curve that detection and testing both lag, so the laboratory-confirmed death rate is a floor on the true figure, not an estimate of it.

Deep Analysis

In plain English

The case-fatality ratio (CFR) is the proportion of people who die out of those known to be infected. For this outbreak, WHO reports a CFR of approximately 14% among laboratory-confirmed cases. But that figure has two important caveats. First, a 6.8:1 ratio of suspected to confirmed cases means that for every person with a laboratory test, nearly seven others are counted only as suspected cases. Many of these suspected patients may be infected but never got tested, either because they died before a swab could be taken, or because they live too far from a functioning laboratory. Some deaths in the suspected group do not count toward the confirmed-case CFR. Second, scientists measure CFR differently depending on which denominator they use. Using confirmed cases gives 14%; using all suspected cases gives roughly 24%. The true figure is somewhere between those two numbers, and public health agencies choose their approach based on what is measurable, not necessarily what is most accurate.

Deep Analysis
Root Causes

The 6.8:1 suspected-to-confirmed ratio has two structural drivers. The first is laboratory throughput: the INRB laboratory in Kinshasa processes samples from Ituri across a cold-chain transport chain, and turn-around times for community samples are two to four days at best. Patients with severe acute haemorrhagic fever often die within four to seven days of symptom onset, meaning a meaningful proportion die before their swab result returns.

The second driver is healthcare-seeking behaviour shaped by community distrust: patients who do not come to treatment centres, or who come only in the terminal phase of illness, are less likely to have a swab taken and processed before death. This connects directly to the treatment-centre arson and M23 access constraints documented in event index 5: a damaged community interface reduces laboratory confirmation rates and therefore inflates the suspected-to-confirmed gap.

First Reported In

Update #5 · Ebola money arrives, the cure does not

World Health Organization· 2 Jun 2026
Read original
Different Perspectives
Imperial College London / Cori and Ferguson
Imperial College London / Cori and Ferguson
Anne Cori and Neil Ferguson place the case-fatality ratio at 30 to 40 per cent and read the 6.8-to-1 suspected-to-confirmed ratio as evidence that the laboratory figure understates true lethality. Many people die before a swab reaches them.
Uganda / Diana Atwine
Uganda / Diana Atwine
Diana Atwine's ministry traced the imported Kampala index case and leant on protocols rehearsed in Uganda's 2022 Sudan ebolavirus response, which contained 142 cases in 113 days without a vaccine. Nine confirmed cases now test whether that playbook holds across two districts.
United States / HHS
United States / HHS
Washington imposed a 21-day entry ban on DRC, Uganda and South Sudan nationals against WHO advice, and sought a 50-bed quarantine site in Nairobi that a Kenyan court suspended on 29 May. The posture rests on a thin federal bench with vacant senior public-health roles.
WHO / Tedros Adhanom Ghebreyesus
WHO / Tedros Adhanom Ghebreyesus
Tedros Adhanom Ghebreyesus called the outbreak 'outpacing us' on 25 May and visited Ituri on 28 May, arguing that stopping transmission depends entirely on humanitarian access. WHO opposes any restriction of travel to or trade with DRC or Uganda.
Africa CDC / Jean Kaseya
Africa CDC / Jean Kaseya
Jean Kaseya declared the continental emergency before WHO and opposed the US travel ban as punishment by passport rather than by exposure. The Africa CDC raised nearly $500 million in days and frames the response as African-led, coordinated from Addis Ababa rather than waiting on Geneva.
European Union / ECDC
European Union / ECDC
ECDC activated an EU Health Task Force, assessed European Bundibugyo import risk as very low, and flagged the recombinant clade Ib/IIb mpox strain in four countries as a surveillance watch item. Both calls reflect the same post-2024 IHR mandate: ECDC acts as a continental early-warning layer rather than waiting for WHO Disease Outbreak News guidance.